Kerwin EM, et al. - In this phase IIb study, researchers determined the safety and efficacy of four doses of the long-acting muscarinic antagonist (LAMA) glycopyrronium (GP) delivered using co-suspension delivery technology via metered dose inhaler (MDI). Findings demonstrated that GP MDI 28.8 μg vs GP MDI 14.4 μg provided no advantage, and added to the evidence from the Phase I/II clinical trial program, which identified GP MDI 14.4 μg as the most appropriate dose for use in the Phase III clinical studies.